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Objectives We hypothesized an impaired renal endocrine and natriuretic response to volume expansion (VE) in humans with
pre-clinical systolic dysfunction (PSD) and pre-clinical diastolic dysfunction (PDD). We further hypothesized that
exogenous B-type natriuretic peptide (BNP) could rescue an impaired natriuretic response in PSD and PDD.
Background Recent reports suggest that in early systolic heart failure (HF), there is an impaired natriuretic response to
acute VE.
Methods PSD was defined as left ventricular ejection fraction 40% without HF symptoms. PDD was defined as ejection
fraction 50%, moderate to severe diastolic dysfunction by Doppler criteria, and no HF symptoms. A double-
blinded, placebo-controlled, crossover study was employed to determine the renal response to VE (0.25 ml/kg/min
of normal saline for 60 min) in the presence and absence of exogenous BNP. Twenty healthy control subjects,
20 PSD subjects, and 18 PDD subjects participated.
Results In healthy control subjects, urinary cyclic guanosine monophosphate (cGMP) and natriuresis increased after VE.
In contrast, among PSD and PDD subjects, there was a paradoxical decrease in urinary cGMP and attenuated
natriuresis. Pre-treatment with subcutaneous BNP resulted in similar increases in both urinary cGMP and natri-
uresis among healthy normal, PSD, and PDD subjects.
Conclusions In PSD and PDD, there is impaired renal cGMP activation, which contributes to impaired natriuresis in response
to VE. Impaired activation of urinary cGMP and reduced natriuresis may contribute to volume overload and the
progression of HF among PSD and PDD subjects. Importantly, the impaired renal excretory response to VE is
rescued by exogenous BNP in PSD and PDD. (J Am Coll Cardiol 2011;58:2095–103) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.042The American Heart Association/American College of
Cardiology define stage B heart failure (HF) as abnormal
heart structure/function in the absence of HF symptoms (1).
With the advancement of cardiac imaging and biomarkers,
abnormal heart structure and function can be detected
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Manuscript received July 6, 2011; accepted July 19, 2011.before the development of symptoms. Pre-clinical, or stage
B, HF can represent either diastolic or systolic dysfunction,
and both are at increased risk of adverse cardiac events and
development of symptomatic HF.
See page 2104
Pre-clinical left ventricular systolic dysfunction (PSD) is
increasingly common among the general population and is
associated with markedly increased risk of progression to
symptomatic HF and death, with a median survival of 7.1
years (2). Further studies suggest that, despite the absence of
signs and symptoms of congestion in PSD, there is impair-
ment of cardiorenal and neuroendocrine regulatory systems
(3,4). Diastolic HF represents 40% to 50% of subjects with
HF (5,6). Similar to PSD, pre-clinical diastolic dysfunction
(PDD) is prevalent in the community (7–9). Importantly,
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that subjects with PDD are at
increased risk of HF and death
similar to that for PSD and
higher than for subjects with
normal diastolic dysfunction (5).
It is well established that the
natriuretic peptide (NP) family,
including atrial natriuretic pep-
tide (ANP) and B-type natri-
uretic peptide (BNP), play an
important role in cardiorenal ho-
meostasis in PSD and HF (10).
Specifically, NP receptor antago-
nism and genetic deletion of the
natriuretic peptide receptor-A
results in an impaired renal re-
sponse to volume expansion (VE)
and hypertension (11,12). These
studies suggest that impairment of
the natriuretic peptide system may
be integral to the pathophysiologic
changes in PSD. However, the
integrated cardiorenal and hu-
moral response to achieve so-
dium homeostasis remains poorly characterized in humans
with PSD and is undefined in PDD.
Despite recent advances in the treatment of overt
symptomatic HF, mortality and morbidity among pa-
tients with HF remains high (13). Further, therapies for
delaying the progression to terminal HF are limited. The
only recommended therapy for PSD is the use of an
angiotensin-converting enzyme inhibitor (14). Reflecting
the absence of proven therapies for diastolic HF, the
recently published heart failure practice guidelines stress the
need to develop and evaluate treatment strategies directed at
patients with pre-clinical diastolic dysfunction (15).
Therefore, the broad objective of the current study was to
define the integrated cardiorenal response to acute VE in
humans with PSD, PDD, and normal cardiac function. We
hypothesized that there is an impaired cardiorenal endo-
crine response to acute VE in PSD and PDD that is
characterized by the lack of appropriate activation of urinary
cyclic guanosine monophosphate excretion (UcGMPV) and
urinary sodium excretion (UNaV). Further, we hypothe-
sized that PSD subjects, PDD subjects, and normal control
subjects would respond similarly to exogenous administra-
tion BNP, which is the most natriuretic of the natriuretic
peptides.
Methods
Study design. We utilized a double-blind, placebo-
controlled, crossover protocol to compare the cardiorenal
and endocrine response to acute VE (0.9% normal saline,
Abbreviations
and Acronyms
ANP  atrial natriuretic
peptide
BNP  B-type natriuretic
peptide
cGMP  cyclic guanosine
monophosphate
DD  diastolic dysfunction
EF  ejection fraction
HF  heart failure
LV  left ventricle
PDD  pre-clinical diastolic
dysfunction
PSD  pre-clinical systolic
dysfunction
SQ  subcutaneous
UcGMPV  urinary cyclic
guanosine monophosphate
excretion
UNaV  urinary sodium
excretion
VE  volume expansion0.25 ml/kg/min for 1 h) after either subcutaneous (SQ)placebo or BNP administration. This study was approved by
the Mayo Foundation institutional review board, and was
performed at the General Clinical Research Center at Mayo
Clinic, Rochester, Minnesota.
Study population. Participants included 20 normal control
subjects, 20 PSD subjects, and 18 PDD subjects. Inclusion
criteria for each group are detailed in the following text, and
baseline characteristics are reported in Table 1.
NORMAL CONTROLS. Normal control subjects had an ejec-
ion fraction (EF) 50%, normal Doppler diastolic func-
ion; no clinical signs, symptoms, or history of cardiovascu-
ar or renal disease; and had never been treated with any
ardiovascular medications.
PRE-CLINICAL SYSTOLIC DYSFUNCTION. The PSD subjects
had an EF 40%; no clinical signs or symptoms of
congestive HF; and a minimal distance on 6-min walk test
of 450 m. If receiving cardiovascular medications, all
doses were stable for at least 2 weeks before the study.
PRE-CLINICAL DIASTOLIC DYSFUNCTION. The PDD sub-
jects had an EF 50%; moderate or severe diastolic dys-
function as assessed by Doppler echocardiography; no clin-
ical signs or symptoms of congestive HF; and a minimal
distance on 6-min walk test of 450 m. If receiving
cardiovascular medications, all doses were stable for at least
2 weeks before the study.
Echocardiographic assessment. Echocardiographic im-
ages were obtained from standard acoustic windows accord-
ing to the recommendations of the American Society of
Echocardiography.
SYSTOLIC FUNCTION. Ventricular volumes (systolic and di-
astolic) were assessed by Biplane Simpsons (method of
disks) analysis obtained from 2 orthogonal cuts of the left
ventricle (LV), apical 4- and 2-chamber, as previously
described (7). The EF was calculated from the volumes as
calculated from the Biplane Simpsons analysis. Stroke
volume was calculated as LV diastolic volume minus LV
systolic volume.
ASSESSMENT OF LV DIASTOLIC FUNCTION AND LV FILLING
PRESSURES. Pulsed-wave Doppler examination of mitral
venous inflow (E) (before and with Valsalva maneuver) and
pulmonary venous inflow as well as Doppler tissue imaging
of the mitral annulus (e=) were performed. Diastolic func-
tion was categorized as previously described (7,16,17),
according to the progression of diastolic dysfunction (DD):
normal; grade 1, impaired relaxation without evidence of
increased filling pressures; grade 1a, impaired relaxation
with evidence of increased filling pressures (mild DD);
grade 2, “pseudonormal” pattern (moderate DD); and grade
3/4, “reversible or fixed restrictive filling” pattern (severe
DD). This diastolic function classification scheme has been
validated against invasive measurement of diastolic function
and filling pressures (17,18) and has been shown to have
independent prognostic value in the general population (7).
sleft ve
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were stabilized for 1 week on a no added salt diet (120 mEq
sodium per day). On the active study day, subjects were
given their usual dose of medications and were placed in the
supine position for 60 min. Subjects were asked to empty
their bladder spontaneously every 30 min (if subjects were
unable to void every 30 min, a urinary catheter was placed).
Adequate bladder emptying was insured by ultrasonogra-
phy. Every 30 min throughout the study, subjects drank an
amount of water equivalent to the sum of the blood losses
and urinary flow. After the 60-min equilibration period, a
30-min baseline clearance was performed. Each clearance
included collecting urine samples over 30 min for determi-
nation of UcGMPV and UNaV. Blood pressure was mea-
sured using an automatic blood pressure cuff, and heart rate
was continuously monitored by electrocardiography. Venous
blood samples were obtained for ANP, BNP, and cGMP
Baseline Characteristics of the Study PopulatioTable 1 Baseline Characteristics of the Stu
Normal Controls
(n  20)
Age, yrs 37 11
Female 85
Body mass index, kg/m2 25 4
Heart rate, beats/min 68 12
Blood pressure, mm Hg
Systolic 116 14
Diastolic 74 9
Hypertension 0
Creatinine, mg/dl 0.9 0.1
Blood urea nitrogen, mg/dl 11 5
Hyperlipidemia 0
Diabetes mellitus 0
Coronary artery disease 0
Myocardial Infarction 0
Cardiovascular medications
ACEI or ARB 0
Nitrates 0
Beta-blocker 0
Digoxin 0
Thiazide diuretic 0
Loop diuretic 0
Aldosterone antagonist 0
Statin 0
LV ejection fraction, % 65 4
LA volume index, ml/m2 22 3
E/e=, medial 7.3 1.6
RVSP, mm Hg 24 3
Atrial natriuretic peptide, pg/ml 21 12
BNP, pg/ml 19 14
Plasma cGMP, pmol/ml 2.6 1.0
Values are mean  SD or %. *p  0.05 versus normal controls, and
normally distributed continuous variables, the rank-sum test for co
independence for categorical variables.
ACEI angiotensin-converting enzyme inhibitor; ARB angiotensin
monophosphate; E/e=  E velocity/e= velocity; LA  left atrium; LV assessment. Echocardiography was performed during thebaseline clearance to determine systolic and diastolic
function.
Immediately after the baseline clearance was performed,
the subjects were randomly assigned to receive either SQ
placebo or SQ BNP (Scios, Mountain View, California [for
safety reasons, the first 10 patients received 5 g/kg and the
ubsequent patients received 10 g/kg]), which was admin-
istered in abdominal SQ tissue. The randomization sched-
ule was provided by the Mayo Clinic Division of Biomedical
Statistics and Informatics and implemented by the Mayo
Clinic Pharmacy. The investigators did not know to which
randomization arm subjects were assigned. Fifteen minutes
after administration of either placebo or SQ BNP, an acute
saline load was administered (normal saline 0.9% 0.25
ml/kg/min for 60 min). Two 30-min clearances were
performed during the 60-min period of VE. Echocardiog-
raphy was repeated immediately after the end of the saline
pulation
Pre-Clinical Systolic
Dysfunction
(n  20)
Pre-Clinical Diastolic
Dysfunction
(n  18)
65 12*† 72 7*
10*† 50*
31 5* 30 5*
68 9† 60 13
119 12† 133 15*
71 8 75 9
35*† 72*
1.1 0.2* 1.1 0.3*
21 10* 23 6*
75* 56*
20 11
65 56*
50 33*
75 61*
10 6
90*† 61*
30*† 0
5† 28*
25 6
20 11
80*† 50*
38 11*† 63 6
35 8* 33 10*
15.7 12.5* 14.0 3.4*
35 9* 33 10*
45 28* 42 32*
111 147* 109 104*
4.5 2.7* 3.9 1.8*
.05 versus pre-clinical diastolic dysfunction as measured by t test for
s variables with a skewed distribution, and the chi-square test for
r blocker; BNP B-type natriuretic peptide; cGMP cyclic guanosine
ntricle; RVSP  right ventricle systolic pressure.ndy Po
†p  0
ntinuou
-receptoinfusion.
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crossover study.
Neurohormonal and electrolyte analysis. Plasma ANP
(Phoenix Pharmaceuticals, Mountain View, California) and
plasma/urine cGMP (PerkinElmer, Shelton, California)
were measured by radioimmunoassay as previously described
(19). Plasma BNP was measured by fluorescence immuno-
assay (Biosite Diagnostics) as described previously (20).
Statistical analysis. Continuous variables were presented
as mean  SD, and categorical variables as percentage.
Comparisons between each of the 3 groups (normal control,
PSD, and PDD) and within groups (baseline, 30 min, and
60 min) were made by t tests for normally distributed
ontinuous variables, the rank-sum test for continuous
ariables with a skewed distribution, and the chi-square test
or independence for categorical variables. For selected
ontinuous variables, the overall change from baseline to
fter volume expansion between groups was compared using
n analysis of variance. All p values are corrected for
ultiple comparisons when performed using a Bonferroni
orrection. For selected continuous variables, we ran addi-
ional comparisons adjusting for age, using an analysis of
ovariance. For these, the comparison was between the
ormal group and each of the other 2 groups (PSD and
DD). For all analyses, statistical significance was accepted
s p  0.05.
esults
tudy population. Baseline characteristics of the normal
control subjects (n 20), PSD subjects (n 20), and PDD
ubjects (n 18) are shown in Table 1. The PSD and PDD
ubjects were older, more likely to be male, and more likely
o have a higher creatinine, blood urea nitrogen, and body
ass index compared to normal controls. The PSD subjects
ere more likely to be male and younger than PDD subjects
ut had similar creatinine, blood urea nitrogen, and body
ass index measurements. Systolic (but not diastolic) blood
ressure and presence of hypertension was higher in PDD
ubjects compared to normal control and PSD subjects. The
resence of coronary artery disease and diabetes mellitus was
imilar between PSD and PDD subjects. Of note, by study
esign, normal control subjects lacked any cardiovascular
omorbidities and took no cardiovascular medications.
ean LV EF was lower in PSD subjects (38%) than in
ormal subjects (65%) and PDD subjects (63%). Medial
velocity/e= velocity (E/e=) and right ventricular systolic
ressure were significantly higher in both the PSD subjects
nd PDD subjects compared to normal control subjects,
uggesting PSD subjects also had a component of diastolic
ysfunction. ANP, BNP, and plasma cGMP were greater in
he PSD and PDD subjects compared to normal control
ubjects, but not different between PSD and PDD subjects.
esponse to VE, placebo pre-treatment. All subjects
nderwent intravascular VE (normal saline 0.9% 0.25 ml/ cg/min for 1 h). Assessment of renal function was per-
ormed at baseline (immediately before VE) and at 30 and
0 min after initiation of VE. Urinary sodium excretion is
hown in Figure 1. Among normal control subjects there
as a significant increase in UNaV at 60 min. In contrast,
here was no significant increase in UNaV in PSD and
DD subjects after VE. The change in UNaV from baseline
o 60 min after VE was not significantly different among the
groups (normal vs. PSD, p  0.09; normal vs. PDD, p 
.59; PSD vs. PDD, p  0.26). Urinary cGMP (Fig. 2A),
hich is known to promote natriuresis, was significantly
ncreased in normal control subjects at 60 min. In contrast,
here was no increase in UcGMPV among subjects with
SD or PDD. Indeed, there was a strong trend toward
educed urinary cGMP in PSD subjects at 30 and 60 min
p  0.08 for both timepoints). Similarly, there was a
ignificant reduction and trend toward reduction (p  0.06)
f urinary cGMP in PDD subjects at 30 and 60 min,
espectively. When we compare the percent change in
rinary cGMP from baseline to after VE, there was a
ignificant difference among the 3 groups (Fig. 2B). Fur-
her, the change in UcGMPV from baseline to 60 min after
E was significantly different among normal control sub-
ects compared to PSD and PDD subjects (normal vs. PSD,
 0.01; normal vs. PDD, p  0.01; PSD vs. PDD, p 
.27). Importantly, adjustment for age did not significantly
lter the results for both UNaV and UcGMPV.
Plasma ANP levels decreased nonsignificantly in PSD
nd PDD subjects after VE. In contrast, plasma ANP levels
ere stable in normal control subjects after VE. The percent
Figure 1 Urinary Sodium Excretion After Volume Expansion
Urinary sodium excretion in normal control, pre-clinical systolic dysfunction
(PSD), and pre-clinical diastolic dysfunction (PDD) subjects at baseline (black
bars), 30 min after volume expansion (white bars), and 60 min after volume
expansion (gray bars). *p  0.05 versus baseline as measured by t test using
a Bonferroni correction for multiple comparisons.hanges in plasma ANP 60 min after VE compared to
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November 8, 2011:2095–103 Volume Expansion in PSD and PDDbaseline were 9.1  53.9%, 10.8  40.5%, and 16.2 
33.7% for normal control subjects, PSD subjects, and PDD
subjects, respectively; there was trend toward a differential
response among the 3 groups but it did not achieve
statistical significance (p  0.18). Plasma BNP and cGMP
levels were not significantly altered in any of the 3 groups
after VE (Table 2).
Figure 2 Urinary cGMP Excretion After Volume Expansion
Urinary cyclic guanosine monophosphate (cGMP) excretion (A) and change in
urinary cGMP excretion from baseline (B) in normal control subjects (normals),
PSD subjects, and PDD subjects at baseline (black bars), 30 min after volume
expansion (white bars), and 60 min after VE (gray bars). *p  0.05, †p 
0.06, §p  0.08 versus baseline as measured by t test using a Bonferroni cor-
rection for multiple comparisons. ‡The p value represents comparison of
change from baseline to VE between groups as measured by 1-way analysis of
variance. Abbreviations as in Figure 1.
Echocardiographic and Humoral Assessment at Baseline and AfterTable 2 Echocardiographic and Humoral Assessment at Baseli
Normal (n  20)
Baseline Volume Expansion
EF, % 64.7 4.4 66.9 3.1 3
SV, ml/beat 85.9 14.2 93.3 13.5 9
E/e=, medial 7.3 1.6 7.2 1.3 1
RVSP, mm Hg 23.7 3.4 24.4 2.9 3
BNP, pg/ml 19 14 20 15 1
Plasma cGMP, pmol/ml 2.6 1.0 2.3 1.5
Values aremean SD. Echocardiographic, BNP, and cGMP assessment was performed at baseline
in echocardiographic assessment, BNP, and cGMP from baseline to volume expansion in the norm
by the rank-sum test for continuous variables with a skewed distribution.
EF  ejection fraction; PDD  pre-clinical diastolic dysfunction; PSD  pre-clinical systolic dysfunctionEchocardiographic parameters at baseline and 60 min
after the initiation of VE are shown in Table 2. Measures of
systolic (EF and stroke volume) and diastolic (medial E/e=
and right ventricular systolic pressure) function were not
significantly altered after VE in normal control, PSD, or
PDD subjects.
Volume expansion and BNP pre-treatment. Utilizing a
double-blind, placebo-controlled study design, we assessed
whether pre-treatment with SQ BNP attenuated the im-
paired natriuretic and urinary cGMP response observed in
PSD and PDD subjects. With BNP pre-treatment, plasma
BNP and cGMP significantly increased in all 3 groups (p
0.05 vs. baseline at 30 and 60 min) (Table 3).
Urinary sodium excretion after VE and no pre-treatment
(placebo) and VE and BNP pre-treatment (BNP) is shown
in Figure 3. Among normal control subjects, there was
significantly greater natriuresis with BNP pre-treatment
compared to placebo. Further, and in contrast to VE alone,
BNP pre-treatment significantly increased UNaV at 30 and
60 min among PSD subjects and at 30 min among PDD
subjects (with a strong trend at 60 min, p  0.07). Similar
to UNaV, and whereas there was a trend toward reduction
in UcGMPV among PSD and PDD subjects with placebo,
there were significant increases in urinary cGMP at 30 and
60 min among PSD and PDD subjects with BNP pre-
treatment (Fig. 4). Importantly, the response to BNP
pre-treatment was similar among all 3 groups for UNaV and
UcGMPV (baseline compared to 60 min; p  0.05 for all
between-group comparisons).
Echocardiographic parameters after VE with placebo
and BNP in all 3 groups are shown in Table 3. There was
a trend for EF to increase and medial E/e= and right
ventricular systolic pressure to decrease with BNP pre-
treatment in all 3 groups, but this did not reach statistical
significance. However, in both the PSD group and the
PDD group, pre-treatment with BNP resulted in an
improvement of diastolic function as assessed by Doppler
criteria (see Methods). In the PSD group, 6 (30%)
subjects had an improvement of diastolic function by 1
grade with BNP pre-treatment compared to 2 (10%)
e Expansiond After Volume Expansion
PSD (n  20) PDD (n  18)
ne Volume Expansion Baseline Volume Expansion
11.3 42.4 10.7 63.3 6.0 66.6 4.7
18.9 99.3 18.7 100.2 23.3 105.4 26.0
12.5 16.7 12.7 14.0 3.4 14.7 4.3
9.3 33.8 10.9 33.1 9.6 33.9 8.3
147 109 137 109 104 101 92
2.7 5.5 8.3 3.9 1.8 3.4 1.3
volume expansion) and immediately after volume expansion. There were no significant differences
trol, PSD, or PDD groups as measured by t test for normally distributed continuous variables andVolumne an
Baseli
7.9
3.7
5.7
4.8
11
4.5
(before
al con; SV  stroke volume; other abbreviations as in Table 1.
e e rank
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Volume Expansion in PSD and PDD November 8, 2011:2095–103subjects with placebo. In the PDD group, 10 (56%)
subjects had an improvement of diastolic function by 1
grade with BNP pre-treatment compared to no subjects
with placebo.
Discussion
This study is the first to describe the cardiorenal response to
VE in PDD subjects and compare it to PSD and normal
subjects. Our results suggest that the renal response to VE
is similarly impaired in both PSD and PDD subjects when
compared to normal subjects. Specifically, renal cGMP
activation paradoxically decreased among PSD and PDD
subjects in response to acute VE, in contrast to an increase
in normal subjects. The lack of activation of renal cGMP
among PSD and PDD subjects was associated with no
significant change in natriuresis compared to a significant
increase among normal subjects. Importantly, administra-
tion of exogenous subcutaneous BNP before VE signifi-
cantly increased urinary cGMP and natriuresis among PSD
and PDD subjects in a manner similar to normal subjects.
These results suggest an impaired natriuretic response to
VE in both PSD and PDD that is rescued by exogenous
BNP administration.
Underscoring the importance of understanding the
pathophysiology of pre-clinical HF is that, despite advances
in the treatment of HF, mortality and morbidity remain
high (13). Importantly, previous studies demonstrate that
although subjects with early HF may be asymptomatic, they
have abnormalities in cardiorenal and humoral adaptations
to sodium loading (3,21). Additional reports suggest that
subjects with PSD have a reduced ability to increase plasma
ANP in response to sodium loading, therefore exhibiting a
tendency to retain sodium (11). The importance of the
natriuretic peptide system in the response to VE in PSD is
further underscored by evidence that antagonism of the
natriuretic peptide receptor-A in an animal model was
associated with significant urinary retention (10). In con-
trast to PSD, there is little information regarding the
pathophysiology of PDD, and to date, there are no reports
Echocardiographic and Humoral Assessment After Volume ExpansiTable 3 Echocardiographic and Humoral Assessment After Volu
Normal (n  20)
Volume Expansion
and Placebo
Volume Expansion
and SQ BNP
Volu
a
EF, % 66.9 3.1 68.0 3.6 4
SV, ml/beat 93.3 13.5 85.5 13.0 9
E/e=, medial 7.2 1.3 7.2 1.5 1
RVSP, mm Hg 24.4 2.9 22.5 3.3 3
BNP, pg/ml 20 15 196 273*
Plasma cGMP, pmol/ml 2.3 1.5 12.8 20.7*
Values are mean  SD. Echocardiographic, BNP, and cGMP assessment was performed immed
xpansion and placebo as measured by t test for normally distributed continuous variables and th
SQ  subcutaneous; other abbreviations as in Tables 1 and 2.regarding the response to VE in PDD.In this study, we report the cardiorenal response to acute
VE in PDD subjects. Specifically, PDD subjects have a
similarly impaired natriuretic response to VE as do PSD
subjects when compared to normal control subjects. This
blunted natriuretic response was associated with impaired
renal activation of cGMP. Although we cannot exclude the
possibility that PSD and PDD subjects may have a delayed
natriuretic response to VE, even a delayed response to VE
may have important negative sequelae on both renal and
cardiac function.
The mechanism for the lack of increase in renal cGMP
activation and natriuresis among PSD and PDD subjects is
likely multifactorial. First, our results suggest a trend toward
a divergent ANP response in PSD and PDD subjects
compared to normal subjects, and decreased plasma ANP
could account for the lack of activation of urinary cGMP
among PSD and PDD subjects. A second mechanism may
be related to up-regulation of phosphodiesterase type 5 in
PSD and PDD, which would result in greater degradation
of cGMP and impaired natriuresis (22). A third potential
mechanism would be down-regulation of natriuretic peptide
receptor-A in the kidney, leading to an impaired urinary
cGMP response (23). It is also possible that the blunted
natriuretic and urinary cGMP response in PSD and PDD
subjects may be partially secondary to the lack of increased
LV filling pressures after VE. However, despite the lack of
increased LV filling pressures in normal control subjects,
there was increased natriuresis and activation of urinary
cGMP, suggesting that mechanisms beyond myocardial
stretch (independent of the heart and cardiac filling pres-
sures) may account for the blunted response in PSD and
PDD. This finding is supported by the observation that in
normal control subjects, there was no increase in plasma
cGMP but significant increases in urinary cGMP, whereas
among PSD and PDD subjects, there was no change in
plasma cGMP but there were decreases in urinary cGMP
after VE. A final potential mechanism is the up-regulation
of neutral endopeptidase, which degrades the natriuretic
peptides and is found most abundantly in the renal tubular
d Placebo or BNP Treatmentxpansion and Placebo or BNP Treatment
PSD (n  20) PDD (n  18)
pansion
cebo
Volume Expansion
and SQ BNP
Volume Expansion
and Placebo
Volume Expansion
and SQ BNP
10.7 43.2 9.7 66.6 4.7 67.3 4.4
18.7 95.6 21.1 105.4 26.0 102.4 25.4
12.7 11.9 1.3 14.7 4.3 12.2 4.7
10.9 30.5 9.9 33.9 8.3 32.6 11.0
137 541 757* 101 92 663 1,550*
8.3 9.6 6.5* 3.4 1.3 10.4 8.5*
fter volume expansion and placebo or SQ BNP pre-treatment. *p  0.05 compared to volume
-sum test for continuous variables with a skewed distribution.on anme E
me Ex
nd Pla
2.4
9.3
6.7
3.8
109
5.5
iately acells (24).
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BNP is able to rescue the impaired renal activation of
cGMP and natriuresis after VE in PSD and PDD subjects.
Specifically, SQ BNP is capable of significantly increasing
urinary cGMP as well as natriuresis in PSD and PDD
subjects to levels comparable to those of normal controls.
These results suggest that, while there is impaired renal
activation of cGMP in PSD and PDD, administration of
Figure 3 Urinary Sodium Excretion After
Volume Expansion With BNP Pre-Treatment
Urinary sodium excretion in (A) normal control subjects, (B) PSD subjects, and (C)
PDD subjects at baseline, 30 min after volume expansion, and 60 min after vol-
ume expansion, after placebo (open bars) or subcutaneous B-type natriuretic pep-
tide (SQ BNP) (solid bars) administration. *p  0.05, ‡p  0.07 versus baseline,
and †p  0.05 versus placebo as measured by t test using a Bonferroni correc-
tion for multiple comparisons. Abbreviations as in Figure 1.SQ BNP is able to overcome this potential pathophysiologicalteration and increase natriuresis. It is important to note
that whereas there were trends toward decreased right
ventricular systolic pressure and medial E/e= after SQ BNP,
they did not achieve statistical significance. It is possible
that with longer duration of treatment, the sodium excretion
properties of SQ BNP would result in significant changes in
LV filling pressures. In combination with previous studies,
Figure 4 Urinary cGMP Excretion After
Volume Expansion With BNP Pre-Treatment
Urinary cyclic guanosine monophosphate (cGMP) excretion in (A) normal con-
trol subjects, (B) PSD subjects, and (C) PDD subjects at baseline, 30 min
after volume expansion, and 60 min after volume expansion, after placebo
(open bars) or subcutaneous B-type natriuretic peptide (SQ BNP) (solid bars)
administration. *p  0.05, ‡p  0.06, §p  0.08 versus baseline, and †p 
0.05 versus placebo as measured by t test using a Bonferroni correction for
multiple comparisons. Abbreviations as in Figure 1.which reported that ANP improved the renal response to
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angiotensin-converting enzyme inhibitor (25), these find-
ings suggest that potentiating the natriuretic peptide system
may improve cardiorenal and humoral function in PSD and
PDD.
Study limitations. The current study has several limita-
tions. First are the different baseline characteristics of the
normal, PSD, and PDD subjects. It is possible that the
baseline differences in age and sex as well as comorbidities
confound the study’s results. However, the baseline charac-
teristics of our patient population are consistent with those
of previous epidemiological studies demonstrating that
there are significant differences in age and sex as well as in
comorbidities between PSD subjects and PDD subjects (7).
By study design, the normal control subjects lacked any
cardiovascular comorbidities and took no cardiovascular
medications to enable a comparison of PSD and PDD
subjects to truly normal control subjects. Importantly, ad-
justment for age in our analysis did not significantly alter our
results. A second limitation is that we did not define a
mechanism for the impaired renal cGMP activation, and
further studies will be required to clarify a mechanism. A
third limitation is that, in the current study, we assessed a
1-time dose of SQ BNP, and future studies will be required
to determine the effects of chronic SQ BNP therapy in
pre-clinical HF.
Conclusions
In summary, we report that both PSD and PDD are
characterized by a lack of activation of urinary cGMP and
natriuresis in response to VE. The lack of appropriate
natriuresis may contribute to volume overload and play a
role in the progression and development of symptomatic
HF. Importantly, administration of SQ BNP resulted in
significant activation of urinary cGMP and natriuresis
among PSD and PDD subjects comparable to that of
normal control subjects. These findings warrant further
studies to determine whether chronic SQ BNP administra-
tion can prevent the progression of PSD or PDD to
symptomatic HF.
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